Stock Events

Stock Events

Search...

Cognetivity Neurosciences

€0

0

+€0+0% Friday 06:00

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

604,755

P/E Ratio

-

Dividend Yield

-

Dividend

-

Earnings

16DecConfirmed

Q3 2020

Q1 2021

Q2 2021

Q3 2021

Q1 2022

Q2 2022

Q3 2022

-0.08

-0.06

-0.03

-0.01

Expected EPS

N/A

Actual EPS

-0.017

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1UB.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Eli Lilly is a major pharmaceutical company that develops drugs for neurological diseases, including Alzheimer's, which competes with CGNSF's cognitive assessment technologies.

Biogen focuses on neurodegenerative diseases, including Alzheimer's disease treatments and diagnostics, directly competing with CGNSF's cognitive testing products.

Pfizer develops medications for various neurological conditions, which can be seen as alternatives to CGNSF's cognitive assessment tools.

Merck is involved in the development of treatments for Alzheimer's disease, competing in the same space as CGNSF's cognitive diagnostics.

Abbott Laboratories

Abbott Laboratories offers a range of healthcare solutions including diagnostics for neurological conditions, overlapping with CGNSF's market.

Sage Therapeutics

Sage Therapeutics develops treatments for central nervous system disorders, which can be used alongside or as an alternative to CGNSF's technologies.

Novartis provides healthcare solutions including neurological disease treatments, competing in the cognitive health space.

Johnson & Johnson

Johnson & Johnson, through its pharmaceutical division, develops treatments for neurodegenerative diseases, competing with CGNSF's cognitive assessment tools.

AC Immune focuses on Alzheimer's disease diagnostics and therapeutics, directly competing with CGNSF's cognitive assessment technologies.

About

Cognetivity Neurosciences Ltd. operates as a technology company. It develops an integrated cognitive assessment, a cognitive testing platform for use in medical, commercial, and consumer environments that allows early diagnosis of dementia; and OptiMind, a wellness app. The company was formerly known as Utor Capital Corp. and changed its name to Cognetivity Neurosciences Ltd. in December 2017. Cognetivity Neurosciences Ltd. was incorporated in 2015 and is headquartered in Vancouver, Canada.

Show more...

CEO

Dr. Sina Habibi

Country

CA

ISIN

CA19243C1005

WKN

000A2JGJZ

Listings